NK cell-related genes-driven novel molecular subtyping and prognostic signatures for Wilms tumor: uncovering the therapeutic potential of TGX-221 and biomarker role of HS2ST1.
Source check: Source checked. Not independent scientific confirmation.
Finding: Original full text, Methods/Results: consensus clustering and LASSO identified Wilms-tumor molecular subtypes and a three-gene survival signature; TARGET-WT n=125 with random internal train/test. TGX-221 claims rely on computational drug prediction/docking; no independent or therapeutic validation.
Technology: Methods identify the ML/deep-learning operation used for the specific result.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Methods identify the ML/deep-learning operation used for the specific result.
- Test and result
- Methods/Results specify cohort, reference/outcome, split or experimental comparator and limitations.
- Limitation / still unknown
- External replication and real-world or clinical benefit were not established by the reviewed study
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1593011/full · https://europepmc.org/article/MED/40951342 · https://pubmed.ncbi.nlm.nih.gov/40951342/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.